Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
$11.34
+16.2%
$8.35
$3.39
$16.00
$148.86M0.88124,683 shs763,929 shs
Cybin Inc. stock logo
CYBN
Cybin
$6.00
-0.7%
$7.22
$4.81
$13.88
$141.30M0.68352,661 shs418,135 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$10.75
+0.4%
$12.86
$9.83
$27.38
$136.85M0.39193,143 shs71,236 shs
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
$0.48
-4.4%
$0.53
$0.39
$3.75
$34.57M-0.021.10 million shs183,973 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
-3.75%-15.93%+8.20%+105.04%+9.91%
Cybin Inc. stock logo
CYBN
Cybin
+0.50%-6.07%-14.45%-23.54%+1,536.86%
Lifevantage Corporation stock logo
LFVN
Lifevantage
+0.28%-9.54%-20.61%-15.20%+7.85%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
+2.28%-0.08%-9.27%-1.77%-78.11%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
$11.34
+16.2%
$8.35
$3.39
$16.00
$148.86M0.88124,683 shs763,929 shs
Cybin Inc. stock logo
CYBN
Cybin
$6.00
-0.7%
$7.22
$4.81
$13.88
$141.30M0.68352,661 shs418,135 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$10.75
+0.4%
$12.86
$9.83
$27.38
$136.85M0.39193,143 shs71,236 shs
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
$0.48
-4.4%
$0.53
$0.39
$3.75
$34.57M-0.021.10 million shs183,973 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
-3.75%-15.93%+8.20%+105.04%+9.91%
Cybin Inc. stock logo
CYBN
Cybin
+0.50%-6.07%-14.45%-23.54%+1,536.86%
Lifevantage Corporation stock logo
LFVN
Lifevantage
+0.28%-9.54%-20.61%-15.20%+7.85%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
+2.28%-0.08%-9.27%-1.77%-78.11%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
3.00
Buy$31.67179.30% Upside
Cybin Inc. stock logo
CYBN
Cybin
3.25
Buy$85.001,317.85% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50183.77% Upside
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
3.00
Buy$7.331,437.39% Upside

Current Analyst Ratings Breakdown

Latest RANI, CYBN, LFVN, and AVTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/17/2025
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$15.00 ➝ $25.00
9/5/2025
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy
9/5/2025
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy
8/15/2025
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight
7/8/2025
Cybin Inc. stock logo
CYBN
Cybin
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$73.00 ➝ $70.00
(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
$440K338.85N/AN/A$12.80 per share0.89
Cybin Inc. stock logo
CYBN
Cybin
N/AN/AN/AN/A$10.83 per shareN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$228.53M0.60$1.11 per share9.72$2.75 per share3.91
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
$1.03M33.28N/AN/A$0.06 per share7.95
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
-$35.13MN/A0.00N/AN/AN/A-48.48%-35.94%11/6/2025 (Estimated)
Cybin Inc. stock logo
CYBN
Cybin
-$57.88M-$4.60N/AN/AN/AN/A-37.58%-36.59%N/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$9.81M$0.7414.57N/A4.29%33.75%15.26%11/4/2025 (Estimated)
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-$30.02M-$0.91N/AN/AN/AN/A-1,258.76%-97.97%11/13/2025 (Estimated)

Latest RANI, CYBN, LFVN, and AVTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/4/2025Q4 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.17$0.17N/A$0.15$57.93 million$55.11 million
8/7/2025Q2 2025
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
-$1.43-$1.92-$0.49-$1.92N/AN/A
8/7/2025Q2 2025
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-$0.19-$0.18+$0.01-$0.18N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
N/AN/AN/AN/AN/A
Cybin Inc. stock logo
CYBN
Cybin
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.67%N/A24.32%3 Years
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
N/AN/AN/AN/AN/A

Latest RANI, CYBN, LFVN, and AVTX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/26/2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.04501.57%9/8/20259/8/20259/16/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
N/A
12.44
12.44
Cybin Inc. stock logo
CYBN
Cybin
N/A
24.24
24.24
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.87
1.11
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
2.75
0.54
0.54

Institutional Ownership

CompanyInstitutional Ownership
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
87.06%
Cybin Inc. stock logo
CYBN
Cybin
17.94%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
30.19%

Insider Ownership

CompanyInsider Ownership
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
0.25%
Cybin Inc. stock logo
CYBN
Cybin
15.00%
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
45.08%
CompanyEmployeesShares OutstandingFree FloatOptionable
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
4013.15 million13.12 millionNot Optionable
Cybin Inc. stock logo
CYBN
Cybin
5023.59 million17.96 millionNot Optionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.69 million10.07 millionOptionable
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
11071.87 million39.47 millionOptionable

Recent News About These Companies

RANI: Second Quarter Financial Results
Rani (RANI) Q2 Net Loss Improves 16%
Rani Therapeutics Holdings, Inc. (RANI) - Yahoo Finance
Rani Therapeutics strikes deal to issue new warrants
RANI: 1Q:25 Financial Results
Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)
Rani Therapeutics management to meet virtually with Lake Street

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Avalo Therapeutics stock logo

Avalo Therapeutics NASDAQ:AVTX

$11.32 +1.56 (+15.98%)
As of 03:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Cybin stock logo

Cybin NYSE:CYBN

$6.00 -0.05 (-0.75%)
As of 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$10.74 +0.03 (+0.28%)
As of 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Rani Therapeutics stock logo

Rani Therapeutics NASDAQ:RANI

$0.48 -0.02 (-4.41%)
As of 03:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.